Listing analysis and research matching research:
Pfizer streamlines research to prepare for post-Lipitor world
Pfizer is going through major structural changes designed to streamline the organisation and position itself for the post Lipitor era. In January 2007 Pfizer announced that it would axe 10% of its global workforce by the end of 2008 to streamline its operations and achieve $2 billion in cost savings. The cuts were expected to lead to the closure of two manufacturing plants (Brooklyn and Omaha) and five research centers in the United States, plants in Japan (Nagoya) and France (Amboise) and the selling of a factory in Germany (Feucht).
Pension funds highlight the importance of collaboration to pharmaceutical companies
A report, sponsored by three pension investment funds the USS, ABP Investment and OPERS, who between them have US $20 billion invested in healthcare, has been released offering one view on the future research and development structure of the pharmaceutical industry.
Johnson & Johnson turns to internal venturing
In a move designed to encourage collaborative ventures between its 230 subsidiaries Johnson & Johnson has recently set up an Internal Ventures Group. Until now Johnson & Johnson had allowed its acquired companies to function largely autonomously in the fields of innovation and research.
Funding research and development through spin-outs
In a bid to cut costs AstraZeneca is spinning out its efforts to find new drugs for gastrointestinal (GI) disorders to a new company called Albireo. Part of the decision reflects AztraZeneca's recent problems with its drug, Nexium, an ulcer treatment, which has been declining in profit and its decision to direct its energies on respiratory, cancer and infectious diseases.
Getting to the bottom of alliance failure rates
Nearly fifty percent of alliances 'fail'. Right? Well no actually.
